Aquestive Therapeutics, Inc. Common Stock AQST
Analyst Ratings
- Consensus
- Buy — 3 Buy · 0 Hold · 0 Sell (3 analysts)
- Avg. Price Target
- $9.33 (+116.0% upside)
Key Stats
- Today's Range
- $4.25 – $4.39
- 50-Day Range
- $3.56 – $5.18
- 52-Week Range
- $2.93 – $7.55
- Volume
- 5.46 million shs
- Average Volume
- 2.80 million shs
- Market Cap
- $538.44 million
- P/E Ratio
- —
- Dividend Yield
- —
Valuation
- P/E Ratio
- —
- Price / Book
- -9.52
- Price / Sales
- 9.96
Short Interest
- Short Interest
- 0.00%
- Days to Cover
- 1.00
Financials (TTM)
- Revenue
- $54.09 million
- Net Income
- $-78,227,000
- Net Margin
- -144.63%
- Return on Equity
- 138.24%
- Debt-to-Equity
- -0.97
About Aquestive Therapeutics, Inc. Common Stock
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif, and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.
Related Stocks
Compare head-to-head: AQST vs LLY·AQST vs JNJ·AQST vs ABBV·AQST vs ABT
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.